Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elisrasib - D3 Bio

Next Previous
Drug Profile

Elisrasib - D3 Bio

Alternative Names: D3S-001

Latest Information Update: 25 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator D3 Bio
  • Class 2 ring heterocyclic compounds; Acetonitriles; Alcohols; Alkenes; Aniline compounds; Antineoplastics; Azabicyclo compounds; Benzoates; Bridged bicyclo compounds; Carbamates; Cyclohexanols; Cyclohexenes; Esters; Fluorinated hydrocarbons; Fluorobenzenes; Heterocyclic bicyclo compounds; Heterocyclic compounds with 4 or more rings; Ketones; Methyl ethers; Piperazines; Pyrans; Pyrimidines; Pyrrolidines; Small molecules; Toluenes; Xylenes
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Colorectal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 25 Sep 2025 Chemical structure information added.
  • 22 Sep 2025 Phase I development for Solid tumours (Monotherapy, Combination therapy, Metastatic disease, Late-stage disease) is ongoing in Germany, Australia, China, France, Hong Kong, Italy, Japan, South Korea, Spain and the US (PO) (NCT05410145)
  • 28 Aug 2025 D3S 001 receives Breakthrough Therapy status for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top